Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary

August 8, 2023

NASDAQ US Health Care Pharmaceuticals earnings 46 min

Earnings Call Speaker Segments

Vivian Wu

executive
#1

Thanks, Crystal, and good afternoon to all of you. We appreciate you being with us today. Joining us on this call are our President and CEO, Howard Robin; our Chief of Research and Development, Dr. Jonathan Zalevsky; our Chief Medical Officer, Dr. Mary Tagliaferri; our Chief Business Officer, Jennifer Ruddock; and Sandra Gardiner, who is serving as our Acting Chief Financial Officer. During this call, we anticipate making forward-looking statements about our business, including statements about the therapeutic potential of and future development plans for drug candidates in research programs, when clinical studies will begin and when clinical data for drug candidates will become available, the timing of and plans for upcoming clinical data presentations, the formation, future development plans, or success of our collaboration agreements, what we expect following our corporate restructuring and reorganization plans, financial guidance, and certain other statements about the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, and many of those lie beyond our control. Our actual results could differ materially from these statements. Key risks and uncertainties appear in our Form 10-Q filed on May 10th, 2023, which you can find at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments, or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com. Before I turn the call over to Howard, I want to mention that Jennifer will be moderating the Q&A session for our team so that we can steer clear of technical issues during the session; we thank you for your patience. Having said that, I would like to hand the call over to our President and CEO, Howard Robin. Howard?

Howard Robin

executive
#2

Vivian, thank you — and thanks to everyone for being here today. For us, the opening six months of this year represented a crucial period; back in April, we rolled out a fresh strategic blueprint centered on our immunology assets while also pushing our cash runway out to at least the midpoint of 2026. Rezpeg stands as our furthest-along candidate, and a sizable Phase 2b trial is set to launch before long in atopic dermatitis patients. I'll cover more on that, along with yesterday's news, shortly. Beyond that, we keep moving our immunology preclinical work forward — a TNFR2 agonist antibody plus a CSF1 program. Our aim is to submit an IND for one of those in 2024. On top of that, the 2 randomized Phase 2 clinical trials for NKTR-255 continue in solid and liquid tumors. Thanks to this new strategic plan, we feel we've built a company well positioned to reach key value-driving phase 2 catalysts across 2024 and 2025. Those milestones should arrive considerably earlier than the cash runway guidance, which carries us into at least the midpoint of 2026. Above all else, we remain dedicated to pushing Rezpeg ahead — our first-in-class regulatory T cell program. Rezpeg is now entirely owned by Nektar. Work is progressing nicely toward kicking off a randomized Phase 2b trial of Rezpeg in atopic dermatitis patients; initial results from that trial should arrive during the first half of 2025. Yesterday, we disclosed that clinical efficacy data Eli Lilly had previously produced for Rezpeg had been miscalculated in both atopic dermatitis and psoriasis; this came to light once every right to Rezpeg had been given back to Nektar and the raw data files from the Rezpeg clinical trials arrived at Nektar. The Lilly internal statistical and clinical teams overseeing those two studies were informed that Nektar had found the data errors, and Lilly verified those errors in writing through written communications with Nektar. Fresh, corrected figures from the atopic dermatitis trial show that 12 weeks of Rezpeg treatment at the top dose produced a mean EASI score improvement of 83% together with an EASI-75 response rate of 41%. Those corrected figures likewise reveal that Rezpeg brought about an extremely swift and sharp decline in EASI scores soon after treatment began — far faster than the biologic therapies currently approved. Among Rezpeg's most compelling features is that once the 12-week induction treatment window ended and dosing ceased, the mean EASI score reduction keeps going for patients tracked in the study. The prospect that Rezpeg might deliver both a mechanism distinct from the current field of IL-13 therapies and a remittive benefit for patients is undeniably intriguing. The biologic treatment landscape in atopic dermatitis is expanding substantially. Approvals of Dupixent alongside other IL-13-based biologics have fueled that expansion. Roughly 16 million individuals live with atopic dermatitis in the US by itself, and 75% of them deal with moderate to severe disease. Back in 2021, sales of biologics for atopic dermatitis came in at just under $5 billion, and those numbers keep climbing. Something like Rezpeg, which does away with the need for regular dosing once the induction treatment period is over, would shake up the multi-billion dollar biologic landscape in atopic dermatitis in a major way; with the options on the market now and those close to approval, patients must keep dosing often to hold onto the benefit, and often, once a therapy is stopped, the eczema atopic dermatitis comes back; we're also aware that a minimum of 50% of patients receiving IL-13 therapies don't respond well enough to treatment. It's obvious that Rezpeg shows real potential for atopic dermatitis patients, and this corrected data strengthens Nektar's strategic plan to put money behind a strong Phase 2b study of Rezpeg. As we said in yesterday's press release, we intend to hold an investor meeting and a key opinion leader meeting in the next few weeks to go over this data and present the study design for the Phase 2b trial of Rezpeg in atopic dermatitis. In a moment, JZ will go into more detail on the corrected Rezpeg data and also cover our early-stage immunology programs. Turning to our oncology asset, NKTR-255, we're still assessing possible strategic partnership options for that program while at the same time carrying on with the Phase 2 clinical trials. I've asked Mary to join us so she can share more on the ongoing clinical studies of NKTR-255. With that, I'll pass the call to JZ to talk about Rezpeg and our preclinical immunology programs. JZ?

Jonathan Zalevsky

executive
#3

Thanks, Howard. To begin with our top immunology asset, Rezpeg is a one-of-a-kind molecule designed to tackle the root Treg shortages and the resulting overactivity of effector T cells seen in autoimmune conditions by selectively activating and growing Tregs. Compared with other therapies either already approved or in development for atopic dermatitis, Rezpeg works through an entirely distinct mechanism. This program stands apart as the most advanced IL-2-based Treg mechanism currently in the clinic. Rezpeg holds promise across numerous autoimmune diseases, and though our current emphasis is atopic dermatitis, future plans include exploring Rezpeg in additional autoimmune indications. As Howard noted, we found that the data Eli Lilly previously reported for Rezpeg had been miscalculated. The biggest problems had to do with errors in calculating the EASI score and the PASI score, as well as in the clinical efficacy endpoints tied to EASI and PASI that were reported at EADV in September 2022, in the atopic dermatitis and psoriasis posters that were shown. This was only uncovered after Nektar had received back all rights to Rezpeg and the raw data files from the Rezpeg clinical studies had been handed over to Nektar. At that point, a leading independent statistical company was engaged to examine the raw data from the beginning, and that company verified that the original statistical analyses Lilly had performed were incorrect. For atopic dermatitis research, EASI has served as the accepted, commonly applied benchmark for more than two decades, used by doctors and documented in published papers. This index captures how severe a patient's atopic dermatitis is, with scores spanning from zero, meaning no illness at all, up to 72, representing the worst possible disease. The interim analysis for the atopic dermatitis trial — corrected and audited — relies on that validated 72-point EASI scale and incorporates every piece of patient information on hand as of the EADV 2022 data cutoff. Based on the data, when patients received Rezpeg at the top dose for 12 weeks, their EASI scores improved by an average of 83%, with a p-value of 0.002 versus placebo, and the EASI-75 response rate came in at 41%. Beyond that strong efficacy, what we saw after 12 weeks of Rezpeg treatment is at least comparable to, or even better than, what has been reported after 16 weeks of dupilumab, which in phase 2a and phase 2b trials demonstrated improvements of 74% and 68%, respectively. One key finding from the new and corrected data was that Rezpeg also produced a swift and sharp decline in EASI scores right after therapy began. To be specific, just 2 doses of Rezpeg produced a mean reduction of minus 71% at week 4 for the highest dose. The corrected data further supports both the remittive effect and the durability of responses to Rezpeg among atopic dermatitis patients. As Howard said, there's a possibility that Rezpeg could, for the first time, deliver a therapy dosed less often than anything currently available to patients, and one that could offer genuine long-term durability. Because of the distinct T regulatory cell approach we intentionally designed, the underlying scientific rationale for why this happens has been theorized for some time. The idea is that activating T regulatory cells might lead to the immune system being re-educated by addressing the root cause rather than merely the disease's symptoms. These clinical results offer, for the first time, a fresh clinical discovery, showing that the Treg mechanism can translate into what effectively appears to be immune system memory, producing both lasting durability and robust efficacy in atopic dermatitis. This marks the initial clinical evidence of a Treg-stimulating treatment working in atopic dermatitis and has Key Opinion Leaders highly excited. The response durability we've seen isn't observed with Dupixent or other agents within the IL-4 and IL-13 class, nor with JAK inhibitors. To repeat what was just said, this makes both our team and key opinion leaders feel very positive about the prospect that Rezpeg could deliver lasting responses with dosing needed only occasionally in patients with atopic dermatitis. As for the remaining efficacy endpoints that were presented at EADV last year, no basic errors of either a formulaic or mathematical nature were found. That said, I want to point out that once every patient's data was incorporated into the updated, corrected dataset, we actually saw some improvement in the vIGA responder endpoint as well as the NRS itch responder endpoint relative to the figures shared previously at EADV. For Rezpeg's highest dose, vIGA rose from 24% reported at EADV to 29%, and for the NRS itch measurement, the boost went from 35% reported at EADV to 41%; regarding psoriasis, endpoints tied to the PASI, PASI were likewise miscalculated for the validated 72-point PASI scoring system. PASI is also the validated and widely utilized standard for more than 20 years, which clinicians use and report in the literature to gauge the severity of psoriasis plaques in patients. The scoring also spans from 0, indicating no disease, to 72 for maximal disease. The corrected and audited final data analysis for the psoriasis study employs the validated 72-point PASI scoring system. Once the data was fixed, it showed a 44% shift from baseline PASI, along with PASI-50 and PASI-75 response rates of 32% and 21% in that order. The statistical and clinical groups running the two Lilly studies were told that Nektar had found the data errors. Lilly's team confirmed those errors through written correspondence with Nektar. In the next few weeks, we plan to hold an investor meeting alongside key opinion leaders. There, we'll present further new results from the atopic dermatitis trial, covering both the 12-week induction phase and the 36-week follow-up period for Rezpeg. Together, these findings strengthen the idea that Rezpeg can provide a remittive effect. We'll also provide additional specifics on the design of a new Phase 2b trial involving biologic-naive patients who have moderate to severe atopic dermatitis and whose condition has worsened despite topical corticosteroids. Our plan is to launch that trial this October, and we anticipate having data during the first half of 2025. Even though our immediate priority for Rezpeg centers on atopic dermatitis, our conviction remains that this drug holds wide-ranging promise across numerous indications. As work on this program moves forward, we will keep assessing additional possibilities and indications for Rezpeg. Now, let's shift to the preclinical immunology research efforts. For 2 autoimmune disease programs, we are pushing our research pipeline ahead. The initial program involves our TNF receptor two, or TNFR2, agonist antibody, which is being developed together with Biolojic Design. Tregs, neuronal cells, and endothelial cells all show high TNFR2 expression, and TNFR2 agonism has been demonstrated to strengthen the suppressive impact and overall functional characteristics of Tregs. If it's absent, that's associated with autoimmune disorders and other inherited conditions that look like FOXP3 loss of function. On the other hand, if it's there, it's been connected to immunoregulatory activity and protective outcomes throughout numerous cell populations and tissues in the body. Working with our collaborator, we've identified 2 lead antibodies that have undergone validation for selective TNFR2 binding, cell type specificity, and TNFR2 agonism in primary human cell-based assays. Development of manufacturing cell lines is currently in progress for the lead antibodies. We, together with the immunology community, have great enthusiasm regarding the TNFR2 target, and our lead TNFR2 agonist antibodies show a favorable biochemical and cellular profile. We're pushing this program ahead quickly as we work toward IND-enabling studies, and our view is that a TNFR2 agonist with selectivity could be hugely valuable in addressing a range of autoimmune conditions. Our second preclinical effort centers on a conjugated form of the CSF-one protein. This molecule was designed so that the receptor-ligand interaction and the exposure are optimized, allowing it to selectively influence how inflammation gets resolved. Normally, CSF-one acts as a cytokine that targets myeloid cells and plays a role in monocyte development as well as monocyte mobilization; when the surrounding cytokine environment is right, CSF-1 produces resolution macrophages of the type that are perfect when an inflammatory response needs to be shut down; in the case of CSF1, we've adjusted the binding properties between ligand and receptor so that a new signal is generated via the CSF1 receptor. We're studying how this biology works across several biologic settings — acute inflammation, chronic inflammation, and fibrosis among them. These programs have us quite enthusiastic, and our intention is to submit an IND during 2024 for a minimum of one of them. As they advance, we're eager to share news about how they're developing. At this point, I'll hand things over to Mary for news about NKTR-255, our oncology effort. Mary?

Mary Tagliaferri

executive
#4

Thanks, JZ. For NKTR-255, we're pursuing two separate paths of development — one focused on solid tumors, and another in liquid tumors alongside cell therapies. Let's begin with the bladder cancer trial. Through our collaboration with Merck KGaA, that company is running a randomized clinical study that pits avelumab against avelumab combined with NKTR-255, given as maintenance treatment for unresectable or metastatic bladder cancer following first-line platinum-based chemotherapy. Our shared scientific theory holds that NKTR-255 will work synergistically with avelumab by producing fresh cytotoxic and memory T cells, along with NK cells, thereby boosting the distinctive ADCC effect that avelumab provides. Given our capacity to take advantage of this dual mechanism of action within the JAVELIN Bladder Medley study, we're enthusiastic about pairing avelumab with NKTR-255. Patient enrollment in the Merck KGaA study remains on schedule. The initial interim analysis of progression-free survival data is set to occur during the second half of 2024. Our other development path involves liquid tumors. Boosting in vivo T cell function, or the fitness of CAR T cells, has remained a central goal for making cellular therapies more effective. A number of studies have by now demonstrated that elevated endogenous IL-15 levels after lymphodepletion correlate with increased CAR T cell expansion and better persistence, along with clinical responses. On the strength of that foundational evidence, we are studying NKTR-255 across one trial sponsored by Nektar and two investigator-sponsored trials, aiming to boost the cellular PK of CAR T cell therapies so that response rates and clinical outcomes improve. We think NKTR-255 could potentially be applied broadly to boost how well cellular therapies work, encompassing autologous and allogeneic CAR T cells as well as other cell therapy products, from TILS through to TCR-based therapies. With that, I'll hand the call to Sandra so she can walk through our financial guidance. Sandra?

Sandra Gardiner

executive
#5

Thanks, Mary. Hello, everyone, and good afternoon. At the close of Q2, we had $409.4 million in cash and investments, and our balance sheet carries no debt. Our projection is still that 2023 will finish with no less than $315 million in cash and investments. In April, we moved quickly to carry out both our restructuring and our strategic plan, and as a result, our financial standing is solid, with a cash runway lasting at least until the middle of 2026. That gets us past a number of important milestones that create value for our pipeline. As we talked about in May, we cut roughly 60% of our workforce based in San Francisco. That staffing cut equals about $30 million annually in reduced operating expenses. Restructuring costs were largely settled during the second quarter, and in this third quarter we've started seeing the savings, with the full annual amount to be achieved in 2024; during Q2, we took a $13.3 million non-cash impairment charge on leased assets. Looking at all of 2023, our current expectation is to report restructuring, impairment, and terminated program costs of roughly $40 million-$45 million, and that figure includes $27 million in non-cash impairment charges booked during the first half of 2023. Now I'll go over the rest of our 2023 financial guidance, which has not changed. We expect GAAP revenue for the whole of 2023 to land between $80 million and $90 million. Within that revenue, $65 million-$70 million comes from non-cash royalties and $15 million-$20 million from product sales; for the full year 2023, we anticipate GAAP R&D operating expenses in the range of $105 million to $115 million, including roughly $15 million-$20 million in non-cash depreciation and stock compensation expense. G&A operating expense for the full year 2023 should come in between $75 million and $80 million, including approximately $15 million-$20 million of non-cash depreciation and stock compensation expense. Non-cash interest expense for the full year 2023 should fall between $20 million and $25 million. As I said before, we expect to finish 2023 with no less than $315 million in cash and investments. At this point, we'd like to take your questions. Operator?

Executive

executive
#6

Oh, hi there, Chen here, calling in on Jay's behalf. Appreciate you taking our question. We've got a few things to ask about Rezpeg, if that's alright. Yeah, congratulations on the revised data from the phase 1b AD trial. So one item that stood out to us — and JZ, you touched on this — is that the updated figures appear to show an even more pronounced early split between the curves, and we're unable to see, say, beyond 70% EASI improvement at week 4 or week 6. I'm just wondering whether you view this as something that could potentially set it apart from other options, and how significant is that early symptom relief according to your market research and KOL feedback? I've got one more question after this.

Howard Robin

executive
#7

Thanks, Chen. JZ-

Jonathan Zalevsky

executive
#8

Yes, absolutely. Thanks for asking that. And you're right to point it out—you noticed in the documents we put out alongside yesterday's press release that there's a drop that's both very quick and quite sharp. That week 4 time point stands out because essentially it comes after patients have received 2 administrations of Rezpeg, with the first at week 0 and the following one at week 2. You observe a fairly pronounced inflection point, and in fact the curve's slope shifts, and you get to a reduction of minus 70% in EASI score, which is pretty fast. Now, this matters a great deal because, keep in mind, with this disease, patients are accustomed to getting topical corticosteroids as treatment. Essentially, those patients anticipate relief coming fairly quickly from putting on a cream. Among the patients in our population, the disease has progressed. Topical corticosteroids no longer keep it under control, and so they're transitioning to systemic biologic therapy, just as they are in our study. Once again, having a response that's really rapid is very beneficial; it benefits the patient greatly, and it benefits expectations greatly. We believe this signals differentiation for Rezpeg, and it aligns quite nicely with how deep the response was that we reported at week 12. Naturally, there's also that other highly differentiated aspect: the extended disease control we saw for 36 weeks following the point when we ceased dosing. All 3 of those aspects truly fit together, and we believe that's among the things stemming from this novel mechanism. I think then you had another question.

Executive

executive
#9

Yeah, thank you. So now that we've got stronger data here, in AD, I'm just interested in how you're viewing the timing, and also how much appetite there is for looking into another opportunity with Rezpeg, perhaps in autoimmune diseases. And I'm also wondering about a possible opportunity even in something like neuroinflammatory diseases. Thank you.

Howard Robin

executive
#10

Yes, I'm able to address that. That's actually a really solid question. At this stage, considering the capital we have and how solid our financial situation is, my preference is for us to concentrate the company on atopic dermatitis at present. Should Rezpeg demonstrate success in atopic dermatitis — and my belief at this point is that it will, given the highly robust data, as you pointed out — then I see potential in additional autoimmune conditions. Even though lupus represents a considerably smaller market than atopic dermatitis, I believe it performed reasonably well in lupus, and there are data corrections in that area we are also reviewing. I genuinely think additional indications exist, such as type one diabetes and food allergy. There are multiple areas in which Rezpeg could be developed, provided we are confident we have a drug that expands regulatory T cells in the right way; as for Nektar right now, our priority is achieving outstanding results in a phase 2b study — a randomized phase 2b study — in atopic dermatitis. After that, should it succeed, we can proceed from there.

Executive

executive
#11

Hello, everybody. Thanks for fielding our questions. Charlie here, filling in for Chris, and I'd also like to say congratulations regarding the corrected Rezpeg data. We have merely a couple of quick items. First, I'm curious whether Lilly gave any rationale for leaving out those three atopic dermatitis patients. I'm just wondering whether a particular justification existed for that exclusion, one that they might have shared. And then, regarding the corrected Rezpeg data, I'm curious whether anything changed with respect to the safety and tolerability findings that were shown last year. Thank you.

Howard Robin

executive
#12

Appreciate that, Charlie. I'll have JZ share his thoughts on both of those questions. JZ, over to you.

Jonathan Zalevsky

executive
#13

Yes, I appreciate it. Thank you for asking. Regarding the information that got left out, that decision really came down to Lilly's own judgment. They chose to apply a set of criteria concerning topical treatments that the protocol allowed. Honestly, from the start, every bit of patient data ought to have been part of this, since the protocol lays out all of that patient information and the employment of each of those elements. Then, your following question concerned safety and tolerability — those findings match what appeared in the EADV presentation. As for what happened on our end at Nektar, we went through all of it. Every component was computed, then computed again. When it comes to the safety data shown at EADV last year, it remains unchanged.

Executive

executive
#14

Thanks. Great. That's very helpful. Thank you so much.

Mara Goldstein

analyst
#15

Fantastic, thank you very much. My apologies—I joined the call late, so please forgive me if I'm covering ground you've already discussed. I have two things to ask. First, in light of the data reanalysis along with the earlier clinical work, is it necessary for you to go to the FDA about this? I realize a trial launch is in your plans, but does the agency have to be informed? That's my first point. My second point concerns the lawsuit—I understand you're unable to say anything because the litigation is ongoing. Could you perhaps just walk us through, from a procedural standpoint, what happens next now that the suit has been filed?

Jennifer Ruddock

executive
#16

Yes, thank you, Mara. Mary, would you handle the FDA portion first, and then I'll have Howard address the second question?

Mary Tagliaferri

executive
#17

Absolutely. When it comes to submitting data to the FDA, that happens through a clinical study report. As of right now, that clinical study report hasn't been finalized yet, and every piece of updated and corrected data will go into it, after which it gets sent to the FDA. With that, I'll hand things over to Howard for the next question, the next portion of the question.

Howard Robin

executive
#18

Okay. On the subject of that litigation — clearly, as you put it correctly, we won't be saying anything about a matter that's currently active. What can be said is that we intend to keep pushing ahead with it, and we're treating it accordingly. Look, this lawsuit is something we regard as extremely serious. It is important; it carries real weight. Consider how Rezpeg has developed — Rezpeg probably could have been running a phase 2 trial in Atopic Dermatitis 1 year back, or 1.5 years back. This lawsuit matters enormously to us; we brought in an outside statistical firm that is very, very well-known and very well-respected, asking them to redo all the calculations from scratch. Essentially we handed over the raw data along with the clinical plan and asked, "What results do you get?" Their corrected figures matched the ones we had produced. We treat this with seriousness. How it unfolds is not something I can address, but obviously it is, it is, it is significant to us.

Analyst

analyst
#19

Hey, everyone. Kambi here, filling in for Roger. What's behind the choice to advance into phase 2b, and why focus on bio-naive patients in particular? Are there any reasons tied to preclinical findings or the mechanism of action that suggest Rezpeg would perform better in that group? Thanks.

Jennifer Ruddock

executive
#20

Thank you, Kambi. JZ, I'll have you take that one.

Jonathan Zalevsky

executive
#21

Absolutely. Thank you, Kambi. One key objective for us was to expand on the phase 1b data we've been discussing today and for which we issued corrected results yesterday. That trial involved patients who had never received biologics. We aimed to keep advancing development within that same group. Given how strong the data we reviewed today looks, along with every differentiating feature Rezpeg offers for these patients, our goal is simply to keep extending that work in the next targeted clinical step for Rezpeg. Regarding your wider question—what this mechanism's applicability is, particularly in atopic dermatitis—one aspect we find rather compelling about the TREG portion of how it works is its genuine potential to function across several lines. Even though our initial emphasis is on biologic-naive individuals, solid scientific grounds exist to anticipate effectiveness in those who've already had biologics too. Take, for instance, people who ceased responding or never responded to an IL-13 treatment such as Dupixent or Adbry, plus additional mechanisms currently being developed—you ought to be able to deliver a TREG element in that post-treatment group too; as part of upcoming development strategies, we'll also be examining the population with prior biologic exposure.

Mary Kate Davis

analyst
#22

Hello, I'm Mary Kate Davis, filling in for Greg Harrison. We appreciate your time in answering our question and walking us through each of the programs. I was examining what might be possible with Rezpeg as well as the route ahead in Atopic Derm. Do you know of any prior cases like this one? And if there are, how did things proceed in those instances?

Howard Robin

executive
#23

So, allow me, allow me, allow me-

Jennifer Ruddock

executive
#24

Yeah.

Howard Robin

executive
#25

Let me try.

Jennifer Ruddock

executive
#26

That's Howard.

Howard Robin

executive
#27

Yeah.

Jennifer Ruddock

executive
#28

Please, go ahead.

Howard Robin

executive
#29

Sure. Regarding whether there are any precedents for this — I'm not aware of any cases where a company has made this type of calculation error, so I really can't offer a comment on that. As for where we go from here, now that we have what I consider to be quite impressive phase 1b data from a randomized trial, we are certainly very excited to advance into phase 2, where I believe we can show that Respeg represents a novel therapeutic mechanism for treating patients with autoimmune disease — Atopic dermatitis in this instance. The lawsuit we filed against Lilly — we will continue working on it. Like I said, it matters enormously to us. I'm not familiar with many precedents for this sort of thing. To my mind, it is an egregious error.

Analyst

analyst
#30

Much appreciated for letting me ask; Jose here, speaking on Boris's behalf. Regarding Rezpeg, is psoriasis still the indication you're looking at next, or have you turned to different ones? I've got something else to ask after.

Mary Tagliaferri

executive
#31

Thank you, Jose. You also have a follow-up question. JZ, please handle the first portion of what she asked.

Jonathan Zalevsky

executive
#32

Absolutely, and thanks. So, one topic that came up during today's discussion was how the PASI score gets calculated, along with the fact that data from EADV had been underreported — something we were glad to fix yesterday. That said, when it comes to the longer-term direction for Rezpeg development, from a dermatology perspective, our attention is squarely on Atopic dermatitis, since that's where we observe extremely strong activity for Rezpeg, as has been covered during this call. Within psoriasis, competing mechanisms of action are already firmly established, like the IL-17 inhibitors. As a result, psoriasis could be something we explore as a possible future development, or perhaps within a lifecycle management framework. At present, in the near term, our dermatology development efforts are concentrated heavily on Atopic dermatitis.

Analyst

analyst
#33

Oh, thanks. Turning to the next item, about the preclinical programs you're advancing that go after TNFR2 as well as CSF1, could you speak broadly about how crowded the competition is for those two targets and what market opportunities you might have there? Thank you.

Jennifer Ruddock

executive
#34

Thanks.

Jonathan Zalevsky

executive
#35

Of course, and I apologize. Yes, I appreciate you asking that. These are obviously early-stage assets, still in the research phase, but I can share some color regarding the targets and where the opportunities lie. When it comes to TNFR2, it's definitely a very hot target right now. Only a handful of companies are emerging that are working on this target and attempting to develop agonistic drugs. Certain companies are zeroing in on oncology uses, while others are zeroing in on autoimmune disease uses. For the TNFR2 target and our agonistic antibodies, we're focused on the autoimmune disease side of things. Now, this is a really distinctive target, since it genuinely governs a great many pathways related to protecting tissue and regenerating tissue, and it's able to act especially well on regulatory T cells after they've relocated into specific compartments within the body, where they encounter varying forms of cytokine pressure. Essentially, NF-κB signaling via the TNF superfamily turns out to be far more essential for propelling their biological significance. We could envision a great deal of use for a TNFR2 agonist antibody in particular organ-related conditions and, you know, somewhat pathology-driven inflammatory states. GI and a group of GI illnesses represent one such area. Neuronal and neuroinflammatory conditions represent another, MS being an example. There truly is a, a spectrum of possibilities for a TNFR2 agonist. As for our CSF1 program, you know, it goes after a myeloid element of the immune system, and it does so intending to produce an immunoregulatory outcome; unlike the other molecules in our pipeline, this one isn't aimed at lymphocytes or T cells, but rather at an entirely different collection of cell populations that regulate and suppress immune activity. We believe that could, once again, also have quite broad use, given that the myeloid compartment takes part in a huge number of diseases, ranging from common, you know, rheumatic conditions to some even more, more uncommon ones too. Thank you for the questions.

Daina Graybosch

analyst
#36

Hello, and thanks. There are a couple of things I'd like to ask. Regarding the recalculated EASI score, could you break down for us how much each of the two modifications mattered — the math mistake on Lilly's side, and then adding in those extra patients? Of the overall added benefit and how quickly that benefit appeared, what portion is attributable to each of those two changes? I have one more question after that.

Jennifer Ruddock

executive
#37

Thank you, Daina. I appreciate that.

Jonathan Zalevsky

executive
#38

Yeah.

Jennifer Ruddock

executive
#39

JZ? Yeah.

Jonathan Zalevsky

executive
#40

My apologies. My apologies, Jennifer. Yes, hello, Dana. Yes, I appreciate you asking. Essentially, most — perhaps even all — of the gap in the figures we shared on Monday stems from how the EASI score is computed mathematically. To illustrate, when the EASI score is computed properly and every piece of patient data is included, the week 12 LS mean results we gave yesterday showed an 83% reduction. When the EASI score is computed properly but the excluded data is not fixed, then the LS mean results at week 12 come to 82%, correct? Those two figures are practically identical. In truth, most of the effect and the shift, right, in the corrected data we reported originated from the mathematical computation of the EASI score.

Daina Graybosch

analyst
#41

That's quite useful, thanks. Now for my follow-up: it appears an error occurred when they configured their stat — feel free to correct me if that's not right. Did that error apply uniformly across every patient, in other words, was some particular column or some particular multiplier always omitted? And does that in fact reveal anything regarding Rezpeg's biology, given that we saw such a substantial benefit because that element was always missing?

Howard Robin

executive
#42

JZ, would you like to address that too?

Jonathan Zalevsky

executive
#43

Yes, absolutely. Thank you. Essentially, whenever you work out the 72 point EASI or PASI score, several elements feed into it — the math that produces that 72 point figure. The initial group is what people generally call the severity scores, so they rate parts of eczema or parts of psoriasis, depending on whether EASI or PASI is being used. Those get rated categorically across four body sections. The following elements of the score actually measure the area. They measure how much skin within each region has disease involvement, and then they factor in that scoring the head involves less dermis than scoring the lower extremities, which involves considerably more. Consistently, the identical mistake occurred in both the EASI and the PASI, which failed to capture all those severity and area elements. Consistently, a score came out below the 72 point score, and that identical mathematical computation was performed for each person at each time point. You know, it was essentially an error, sort of like something in the code, you know, that was used to perform the calculation. A couple of key things to, to add there, you know, to sort of, you know, finish the thought behind your question, is that truly, for more than 20 years, just one measure has been used for either, you know, Atopic derm or psoriasis studies. Not only is it validated, you know, but these are the central endpoints that have appeared in study after study after study, plus just in use in dermatology clinics. The sole score is a 72-point score. Anything apart from that isn't even an apple-to-apple kind of a comparison. I hope that addresses your question and provides some additional color around this.

Howard Robin

executive
#44

Alright, thanks to each of you for being here with us today. Our attention continues to be on carrying out the work needed to advance Rezpeg along with the research programs centered on immunology. Naturally, I want to express appreciation to every one of our staff members for what they do and for the remarkable dedication they bring. My thanks also go out to those who hold shares in our company for standing behind us; we're eager to bring you news about how things are moving forward, so keep watching. Once more, I appreciate your presence here today.

Operator

operator
#45

That brings us to the end of this conference call. We appreciate everyone joining us. You can go ahead and disconnect at this point. Have a great day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.